Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 272

1.

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.

Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, Wang YC, Pazdur R; FDA.

Clin Cancer Res. 2005 May 15;11(10):3604-8.

2.

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.

Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R.

Oncologist. 2005 Mar;10(3):176-82. Review.

3.

Advances in myelodysplastic syndrome: nursing implications of azacitidine.

Demakos EP, Linebaugh JA.

Clin J Oncol Nurs. 2005 Aug;9(4):417-23. Review.

PMID:
16117208
4.

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA; Cancer and Leukemia Group B.

J Clin Oncol. 2006 Aug 20;24(24):3895-903.

PMID:
16921040
5.

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.

Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, McIntyre HJ, Fernando IJ, Backstrom JT, Beach CL.

J Clin Oncol. 2009 Apr 10;27(11):1850-6. doi: 10.1200/JCO.2008.17.1058. Epub 2009 Mar 2.

PMID:
19255328
6.
7.

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.

Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias.

Cancer. 2010 Mar 15;116(6):1485-94. doi: 10.1002/cncr.24894.

8.

Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes.

Uchida T, Ogawa Y, Kobayashi Y, Ishikawa T, Ohashi H, Hata T, Usui N, Taniwaki M, Ohnishi K, Akiyama H, Ozawa K, Ohyashiki K, Okamoto S, Tomita A, Nakao S, Tobinai K, Ogura M, Ando K, Hotta T.

Cancer Sci. 2011 Sep;102(9):1680-6. doi: 10.1111/j.1349-7006.2011.01993.x. Epub 2011 Jul 12.

9.

Safety and efficacy of azacitidine in myelodysplastic syndromes.

Vigil CE, Martin-Santos T, Garcia-Manero G.

Drug Des Devel Ther. 2010 Sep 24;4:221-9. Review.

10.

A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.

Venditti A, Tamburini A, Buccisano F, Scimò MT, Del Poeta G, Maurillo L, Cox MC, Abruzzese E, Tribalto M, Masi M, Amadori S.

Ann Hematol. 2000 Mar;79(3):138-42.

PMID:
10803936
12.

Azacitidine. Poor-prognosis myelodysplasia: promising, but more data needed.

[No authors listed]

Prescrire Int. 2011 Feb;20(113):40.

PMID:
21488589
13.

Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia.

Font P.

Adv Ther. 2011 Mar;28 Suppl 3:1-9. doi: 10.1007/s12325-011-0002-8. Epub 2011 Mar 9. Review.

PMID:
21431628
14.

Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome.

List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R.

Blood. 1997 Nov 1;90(9):3364-9.

15.

Treatment of acute myelogenous leukemia with outpatient azacitidine.

Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y, Lister J.

Cancer. 2006 Oct 15;107(8):1839-43.

16.

Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.

Silverman LR, Holland JF, Weinberg RS, Alter BP, Davis RB, Ellison RR, Demakos EP, Cornell CJ Jr, Carey RW, Schiffer C, et al.

Leukemia. 1993 May;7 Suppl 1:21-9.

PMID:
7683352
17.

Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.

Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N.

Cancer. 2008 Oct 1;113(7):1596-604. doi: 10.1002/cncr.23789.

18.

A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.

Martin MG, Walgren RA, Procknow E, Uy GL, Stockerl-Goldstein K, Cashen AF, Westervelt P, Abboud CN, Kreisel F, Augustin K, Dipersio JF, Vij R.

Am J Hematol. 2009 Sep;84(9):560-4. doi: 10.1002/ajh.21482.

19.

Azacitine (vidaza) for myelodysplastic syndrome.

[No authors listed]

Med Lett Drugs Ther. 2005 Jan 31;47(1201):11.

PMID:
15678015
20.

Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes.

Marcucci G, Silverman L, Eller M, Lintz L, Beach CL.

J Clin Pharmacol. 2005 May;45(5):597-602.

PMID:
15831784

Supplemental Content

Support Center